RAHWAY, N.J., February 04, 2025 -- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, ...
Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
Merck Foundation and First Ladies of Africa mark World Cancer Day 2025: 194 Oncology Scholarships Provided Across 32 African ...
Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China ...